Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,208.12 +80.43 (+7.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? ↗
Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen. 
Via The Motley Fool
News headline image
Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant? ↗
Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once. 
Via The Motley Fool
News headline image
3 Penny Stocks Under $5 Backed by Real Revenue Growth ↗
These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside 
Via MarketBeat
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentals ↗
Via Chartmill
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out. 
Via MarketBeat
Topics ETFs
News headline image
3 Reasons to Buy Eli Lilly Stock ↗
Despite several setbacks over the past year, the drugmaker marches on. 
Via The Motley Fool
News headline image
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
These companies don't typically compete directly with one another, but that might change soon. 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗
Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 12.92% on an annualized basis producing an average annual ... 
Via Benzinga
News headline image
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own ↗
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINK ↗
The iShares U.S. Healthcare ETF (IYH) tracks a broad healthcare index, while the Simplify Health Care ETF (PINK) gives an active manager more room to choose. That difference matters for investors... 
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
After a few days of purging, the Ark Invest growth investor is buying stocks again. 
Via The Motley Fool
News headline image
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound ↗
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound. 
Via MarketBeat
News headline image
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy? ↗
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals. 
Via The Motley Fool
Topics ETFs
News headline image
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability. 
Via The Motley Fool
Topics ETFs
News headline image
3 Underrated Dividend Stocks That Could Generate Reliable Cash Flow for Your Portfolio for Decades ↗
These stocks may not be your first choices when looking for dividends, but they have been income-generating machines for years. 
Via The Motley Fool
News headline image
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? ↗
These two healthcare leaders have a long history of competing against one another. 
Via The Motley Fool
News headline image
Health Care ETFs: XLV Delivers Low Fees and Solid Returns ↗
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026? ↗
Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles. 
Via The Motley Fool
Topics ETFs
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
1 Profitable Stock to Target This Week and 2 We Avoid
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution? ↗
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Eyes Label Expansion For Leukemia Drug ↗
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL. 
Via Benzinga
News headline image
Should You Buy Eli Lilly Stock Now or Wait for a Dip? ↗
Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation. 
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
Let’s dig into the relative performance of Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings seaso... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ↗
Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels. 
Via The Motley Fool
News headline image
Meet the Spectacular Vanguard ETF That Could Buy SpaceX Stock as Soon as June 19 ↗
The Vanguard Mega Cap Growth ETF owns a concentrated portfolio of America's largest companies. 
Via The Motley Fool
Topics ETFs
News headline image
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments. 
Via The Motley Fool
News headline image
These 3 Stocks With Fast-Growing Dividends Can Help You Beat Inflation ↗
Eli Lilly, Parker-Hannifin, and Microsoft all have grown their dividend by 50% or more over the past five years, but still have plenty of room for dividend growth. 
Via The Motley Fool
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.